Woodline Partners LP Esperion Therapeutics, Inc. Transaction History
Woodline Partners LP
- $14.3 Billion
- Q1 2025
A detailed history of Woodline Partners LP transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 1,503,754 shares of ESPR stock, worth $2.69 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,503,754
Previous 1,503,746
-0.0%
Holding current value
$2.69 Million
Previous $3.31 Million
34.55%
% of portfolio
0.02%
Previous 0.02%
Shares
9 transactions
Others Institutions Holding ESPR
# of Institutions
197Shares Held
117MCall Options Held
171KPut Options Held
679K-
Black Rock Inc. New York, NY14MShares$25 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$21 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT10.9MShares$19.6 Million0.09% of portfolio
-
Two Seas Capital LP Rye, NY9.95MShares$17.8 Million0.18% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.69MShares$17.4 Million0.32% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $119M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...